ArticleScientific reports2022
A derived honey bee stock confers resistance to Varroa destructor and associated viral transmission.
Article in Scientific reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Biological costs and benefits of selective breeding for disease resistance using marker-assisted or field-based selective breeding in honey bees (Apis mellifera).Journal of economic entomology · 2026Article
- Honey bee hygienic selection impacts virus dynamics of both bees and Varroa mites.Virus research · 2026Article
- Honey bee genetic resistance outperforms a cold-storage induced halt in brood production to control mites and viruses.Scientific reports · 2026Article
- Viruses and vectors tied to honey bee colony losses.PLoS pathogens · 2026Article
- Article
- Hangry bees: Pollen dearth impacts honey bee (Apis mellifera) behavior and physiology.PloS one · 2026Article
- Review
- Article
- Avoiding the tragedies of parasite tolerance in Darwinian beekeeping.Proceedings. Biological sciences · 2025Review
- Honey bees bred for Varroa sensitive hygiene trait demonstrate resistance to chalkbrood disease.PloS one · 2025Article
- Selection of Honey Bee (Animals : an open access journal from MDPI · 2024Article
- Potassium ion channels as a molecular target to reduce virus infection and mortality of honey bee colonies.Virology journal · 2023Article
- Molecular Detection and Phylogenetic Analysis of Deformed Wing Virus and Sacbrood Virus Isolated from Pollen.Veterinary sciences · 2023Article
- Nationwide Screening for Bee Viruses inInsects · 2023Article
- Honey Bee Genetic Stock Determines Deformed Wing Virus Symptom Severity but not Viral Load or Dissemination Following Pupal Exposure.Frontiers in genetics · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The ectoparasite Varroa destructor is the greatest threat to managed honey bee (Apis mellifera) colonies globally. Despite significant efforts, novel treatments to control the mite and its vectored pathogens have shown limited efficacy, as the host remains naïve. A prospective solution lies in the development of Varroa-resistant honey bee stocks, but a paucity of rigorous selection data restricts widespread adoption. Here, we characterise the parasite and viral dynamics of a Varroa-resistant honey bee stock, designated 'Pol-line', using a large-scale longitudinal study. Results demonstrate markedly reduced Varroa levels in this stock, diminished titres of three major viruses (DWV-A, DWV-B, and CBPV), and a two-fold increase in survival. Levels of a fourth virus that is not associated with Varroa-BQCV-do not differ between stocks, supporting a disruption of the transmission pathway. Further, we show that when decoupled from the influence of Varroa levels, viral titres do not constitute strong independent predictors of colony mortality risk. These findings highlight the need for a reassessment of Varroa etiology, and suggest that derived stocks represent a tractable solution to the Varroa pandemic.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.